Stockscreener 앱 받기
223.26
0.08%
-0.17
시간 외 거래:
221.07
-2.19
-0.98%
전일 마감가:
$223.43
열려 있는:
$223.42
하루 거래량:
6.77M
Relative Volume:
1.07
시가총액:
$394.59B
수익:
$61.16B
순이익/손실:
$4.20B
주가수익비율:
94.32
EPS:
2.3671
순현금흐름:
$19.68B
1주 성능:
-1.05%
1개월 성능:
+1.44%
6개월 성능:
+12.73%
1년 성능:
+17.14%
1일 변동 폭
$220.12
$223.96
1주일 범위
$204.27
$228.70
52주 변동 폭
$164.39
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.26 | 394.89B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
LLY
Lilly Eli Co
|
1,044.67 | 947.09B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.64 | 578.21B | 94.19B | 26.80B | 20.46B | 11.05 |
|
NVS
Novartis Ag Adr
|
157.05 | 298.47B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
MRK
Merck Co Inc
|
117.65 | 302.63B | 65.00B | 18.26B | 13.05B | 7.2751 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie, Astra Lose Appeal Over Louisiana Contract Pharmacy Law - Bloomberg Law News
Is Abbvie Stock Overvalued in 2026 After a 15% Rally Last Year? - TIKR.com
AbbVie Insiders Sell US$41m Of Stock, Possibly Signalling Caution - 富途牛牛
BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating - marketscreener.com
DOJ Drops Challenge To AbbVie's $1.6B Break Fee Deduction - Law360
AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next - TechStock²
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological CancersLupin | Press Release - lupin.com
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week - Seeking Alpha
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next - TechStock²
AbbVie (ABBV) Receives a Buy from Guggenheim - The Globe and Mail
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
AbbVie upgraded by Moody’s to A2 with stable outlook - Investing.com Nigeria
Top Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on AbbVie stock - Investing.com
Evercore ISI Group Lowers Price Target for AbbVie (ABBV) to $228 - GuruFocus
(02/06/26) Top Picks 2026: AbbVie Inc. (ABBV) - moneyshow.com
AbbVie Earnings Call: New Growth Engines Take Lead - The Globe and Mail
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss - TechStock²
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game - BioPharma Dive
Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating - marketscreener.com
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal - Finviz
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal - MarketBeat
AbbVie (ABBV) Receives a Neutral Rating as UBS Lowers Price Targ - GuruFocus
UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating - marketscreener.com
AbbVie Submits Regulatory Applications for Rinvoq in Patients with Vitiligo - Contract Pharma
AbbVie: The Market Is Getting It Wrong - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript - Insider Monkey
AbbVie shares slide on perceived Humira reliance - The Pharma Letter
AbbVie Shares Fall as Wall Street Focuses on Filler Weakness - The Business of Fashion
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds - Finviz
Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth - TradingView
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything But It's A Lot (NYSE:ABBV) - Seeking Alpha
AbbVie Earnings: Skyrizi Holds Steady Share Despite Competition - morningstar.com
AbbVie Inc. (ABBV) Shares Slide as Revenue Beat and Raised 2026 Outlook Fail to Stem Sell-Off - AlphaStreet News -
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - The Globe and Mail
AbbVie Q4 Earnings Call Highlights - Yahoo Finance
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise (ABBV) - Seeking Alpha
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake (NYSE:ABBV) - Seeking Alpha
AbbVie’s Deal Focus Is Not Just Early-Stage Assets - Citeline News & Insights
ABBV AbbVie Inc. Feb 2026 Evercore Maintains Outperform, PT lowered to $228 - Meyka
AbbVie Inc (ABBV) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
AMD, AbbVie, Boston Scientific, Eli Lilly, MP, Super Micro, Palantir, and More Movers - Barron's
AbbVie forecasts upbeat 2026 profit, but shares fall on key drug’s sales miss - WTVB
AbbVie’s Rinvoq Vitiligo Bid Raises Questions On Growth And Valuation - Yahoo Finance
AbbVie's Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade) (NYSE:ABBV) - Seeking Alpha
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense - TipRanks
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates - TechStock²
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
3.51%
자본화:
|
볼륨(24시간):